ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 153 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2017. The put-call ratio across all filers is 2.51 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $2,085,000 | +13.0% | 46,985 | -0.2% | 0.01% | +16.7% |
| Q2 2018 | $1,845,000 | -28.2% | 47,061 | +32.5% | 0.01% | +100.0% |
| Q1 2018 | $2,568,000 | -1.3% | 35,514 | -10.2% | 0.01% | 0.0% |
| Q4 2017 | $2,603,000 | -5.7% | 39,528 | -28.3% | 0.01% | 0.0% |
| Q3 2017 | $2,761,000 | +15.4% | 55,095 | +6.6% | 0.01% | 0.0% |
| Q2 2017 | $2,392,000 | +1096.0% | 51,667 | +508.1% | 0.01% | +500.0% |
| Q3 2015 | $200,000 | -93.8% | 8,496 | -78.5% | 0.00% | -87.5% |
| Q2 2015 | $3,229,000 | – | 39,489 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
| Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
| Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
| BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
| Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
| PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
| Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
| Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
| Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
| SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |